Helicobacter Pylori Resistance
Conditions
Keywords
Gastrointestinal Symptom Rating Scale, Helicobacter pylori resistance, levofloxacin, Sydney score
Brief summary
The main goal of the study was to characterize the morbidity, immunological, microbiolical and clinical phenotypes of patients with treated- resistance to Helicobacter pylori (HP) infection, and the effect of triple therapy including the levofloxacin. Control groups were newly diagnosed, previously infected and never infected HP patients
Detailed description
See Nestegard O, et al. PLOS ONE \| https://doi.org/10.1371/journal.pone.0238944 September 23, 2020
Interventions
DRUGlevofloxacin, amoxicillin, clarithromycin
Triple therapy of Helicobacter pylori including two antibiotics and a proton inhibitor for 10 days
Sponsors
University Hospital of North Norway
Study design
Observational model
CASE_CONTROL
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Patients referred to a GI- unite with upper GI complains and performing an upper endoscopy -
Exclusion criteria
Patients with severe chronic diseases and not willing to participate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Characterization of patients with chronic HP infection resistant to previous conventional triple therapy | 2010-2012 | Clinical data including endoscopy, histology, microbiological data including resistance measurements, immunological data (mucosal tranacrips), effect of triple therapy |
| Endoscopy | 2010-2012 | endoscopic description of mucosa bye endoscopy |
| Histology | 2010-2012 | Histological characterizations of inflammation (Sydney) of gastric mucosa |
| Immunology | 2010-2012 | Immunological mucosal characterizations of pro- and antiinflammatory cytokine transcript (PCR) |
| HP microbiology | 2010-2012 | HP microbiology sensitivity to metronidazol, amoxicillin, clarithromycine, levofloxacin and tetracycline |
Outcome results
None listed